Implementation of Alere i Influenza A & B point of care test for the diagnosis of influenza in an ED

Am J Emerg Med. 2018 Jun;36(6):916-921. doi: 10.1016/j.ajem.2017.10.046. Epub 2017 Oct 18.

Abstract

Study objective: This study aimed to evaluate the impact of implementing rapid point-of-care testing (POCT) with the Alere i Influenza A & B in an emergency department (ED) during an influenza epidemic.

Methods: Direct nasal swabs were prospectively collected following the physical examination of patients aged >18years who presented to the ED of a tertiary hospital in France with influenza-like illness (ILI) symptoms (N=301) between February 1st and March 31st, 2016, which coincided with an influenza epidemic. Laboratory-based testing (standard of care) was used to obtain a diagnosis in February 2016 (pre-POCT cohort) and positive results were confirmed using polymerase chain reaction. The primary endpoint was patient time in the ED.

Results: A total of 169 and 132 patients participated in the pre-POCT phase and POCT phase respectively. A significantly higher proportion of patients received a positive diagnosis in the POCT cohort compared with the pre-POCT cohort (31% versus 5.3%, P<0.01). Mean time spent in the ED and hospitalization rate were significantly lower in the POCT cohort (6.06h versus 4.15h, P=0.03, and 44.4% versus 9.7%, P=0.02, respectively). Despite similar rates in the prescription of antibiotics and antiviral therapies, the proportion of patients who were referred for additional tests was significantly lower in the POCT cohort (78.1% versus 62.1%, P=0.003, and 80.5% versus 63.6%, P=0.01, respectively).

Conclusions: The Alere i Influenza A & B POCT reduced the length of stay in ED, the hospitalization rates, and the number of additional diagnostic tests compared with standard of care testing.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • DNA, Viral / analysis*
  • Emergency Service, Hospital*
  • Female
  • France / epidemiology
  • Humans
  • Incidence
  • Influenza A virus / genetics*
  • Influenza B virus / genetics*
  • Influenza, Human / diagnosis*
  • Influenza, Human / epidemiology
  • Influenza, Human / virology
  • Male
  • Middle Aged
  • Point-of-Care Testing*
  • Prospective Studies
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • DNA, Viral